Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 3Thoracic 2Gastrointestinal 2Tumor-Agnostic 1Plasma cell 1Other solid neoplasm 1Head & Neck 1Gynecologic 1CNS 1Breast 1

Conditions

Neoplasms 1Head and Neck Neoplasms 1Carcinoma, Squamous Cell 1

Interventions

pembrolizumab 166Cisplatin 112Cetuximab 76Nivolumab 52Carboplatin 51Fluorouracil 48Paclitaxel 42Docetaxel 37Gemcitabine 30Radiotherapy 28Capecitabine 19Cyclophosphamide 18durvalumab 17Injections 17lenvatinib 16atezolizumab 16cemiplimab 15spartalizumab 13fludarabine 13avelumab 12Ipilimumab 12Pemetrexed 11130-nm albumin-bound paclitaxel 11Oxaliplatin 10Gefitinib 10tremelimumab 9Drug Therapy 9tislelizumab 8epacadostat 8budigalimab 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Pharmaceutical Preparations × Head & Neck × Clear all
NCT00547157 2017-03-15

Radiotherapy Plus Panitumumab Compared to Chemoradiotherapy With Unresected, Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Amgen

Phase 2 Completed
152 enrolled 18 charts
Head & Neck

Carcinoma, Squamous Cell, Head and Neck Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡